TaiGen Enters Exclusive License Agreement with YSP

TaiGen Biopharmaceuticals Holdings Ltd. announces that TaiGen Biotechnology, a subsidiary company of TaiGen, have signed an exclusive licensing agreement with Y.S.P. Industries (M) Sdn. Bhd. to develop and commercialize TaiGen's new drug in Malaysia and Singapore. TaiGen indicates that the agreement involves the development and marketing rights of the new drug in Malaysia and Singapore. Y.S.P. Industries (M) Sdn. Bhd. will be responsible for the New Drug Application (NDA) and market sales within the authorized region. The contract duration starts from the signing date and lasts for 20 years from the initial product sale. Kuo-Lung Huang, Chairman and Chief Executive Officer of TaiGen, said, "The YSP Group has deep roots in Taiwan, and its subsidiary, Y.S.P. Industries (M) Sdn. Bhd., boasts over 30 years of outstanding experience in pharmaceuticals, drug development, and sales in Malaysia and Singapore. In collaboration with Y.S.P. Industries (M) Sdn Bhd., TaiGen is now expanding into the Southeast Asia market, offering a new selection of medication to meet the local medical needs. This partnership marks another significant milestone for TaiGen in terms of licensing its product overseas." Both parties, in consideration of the competitiveness of the pharmaceutical market and concerns about proprietary information, currently refrain from disclosing the name of the new drug. About YSP Industries (M) Sdn. Bhd. Y.S.P. Industries (M) Sdn. Bhd. is a wholly-owned subsidiary of Malaysia-listed company Y.S.P. Southeast Asia Holding Berhad ("YSPSAH") (Stock code: 7178.KL). With over 30 years of expertise in pharmaceutical manufacturing, development, and marketing, YSPSAH also owns pharmaceutical warehousing and logistics facilities. It boasts a diverse product portfolio of more than 800 items, including prescription drugs, over-the-counter medicines, animal and aquaculture pharmaceuticals, traditional formulations, and medical health-related products. Its market presence spans across Southeast Asia, Africa, and Middle Eastern countries. The company's products are distributed through 120 hospitals, 4,500 clinics, 1,450 pharmacies, and 500 Traditional Chinese medicine clinics. About TaiGen Biotechnology Co. Ltd. TaiGen Biotechnology, with a subsidiary in Beijing, China, was founded in 2001 and became listed on the Taiwan OTC Stock Market in 2014. TaiGen is a fully-integrated pharmaceutical company dedicated to the development of innovative small molecule drugs (New Chemical Entity, NCE) with a focus on anti-infective drug research. It has extensive experience in research topic selection, drug discovery, drug development, and regulatory approval. The company possesses the capability to conduct multi-country, multi-center clinical trials and has a track record of overseas licensing. Its flagship product, non-fluorinated quinolone antibiotic Taigexyn® (Nemonoxacin), has obtained marketing approvals in Taiwan, mainland China, and Russia. The influenza antiviral TG-1000 has completed the phase II clinical trial and out-licensed the development and commercialization rights in mainland China.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!